HK1063005A1 - Methods to mobilize progenitor/stem cells - Google Patents

Methods to mobilize progenitor/stem cells

Info

Publication number
HK1063005A1
HK1063005A1 HK04104446.8A HK04104446A HK1063005A1 HK 1063005 A1 HK1063005 A1 HK 1063005A1 HK 04104446 A HK04104446 A HK 04104446A HK 1063005 A1 HK1063005 A1 HK 1063005A1
Authority
HK
Hong Kong
Prior art keywords
sub
atoms
nitrogen
formula
fused
Prior art date
Application number
HK04104446.8A
Other languages
English (en)
Inventor
Gary J Bridger
Michael J Abrams
Geoffrey W Henson
Ronald Macfarland
Gary B Calandra
Dale C David
Hal E Broxmeyer
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26976666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1063005(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anormed Inc filed Critical Anormed Inc
Publication of HK1063005A1 publication Critical patent/HK1063005A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
HK04104446.8A 2001-07-31 2004-06-18 Methods to mobilize progenitor/stem cells HK1063005A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30919601P 2001-07-31 2001-07-31
US38215502P 2002-05-20 2002-05-20
PCT/US2002/024212 WO2003011277A2 (en) 2001-07-31 2002-07-30 Methods to mobilize progenitor/stem cells

Publications (1)

Publication Number Publication Date
HK1063005A1 true HK1063005A1 (en) 2004-12-10

Family

ID=26976666

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04104446.8A HK1063005A1 (en) 2001-07-31 2004-06-18 Methods to mobilize progenitor/stem cells

Country Status (29)

Country Link
US (9) US6987102B2 (ko)
EP (3) EP2371361B1 (ko)
JP (2) JP5137288B2 (ko)
KR (2) KR20040020075A (ko)
CN (2) CN102302493B (ko)
AT (1) ATE538785T1 (ko)
AU (1) AU2002318927B2 (ko)
BE (1) BE2019C544I2 (ko)
BR (1) BRPI0211570B8 (ko)
CA (1) CA2455559C (ko)
CY (4) CY1112633T1 (ko)
DK (2) DK2371361T3 (ko)
ES (2) ES2742730T3 (ko)
FR (2) FR12C0042I1 (ko)
HK (1) HK1063005A1 (ko)
HU (1) HUP0402360A2 (ko)
IL (2) IL159312A0 (ko)
LT (2) LT2371361T (ko)
LU (2) LU92033I2 (ko)
MX (1) MXPA04000982A (ko)
NL (2) NL300537I2 (ko)
NO (4) NO336989B1 (ko)
NZ (1) NZ530169A (ko)
PL (1) PL364673A1 (ko)
PT (2) PT2371361T (ko)
RU (1) RU2309741C2 (ko)
SI (2) SI2371361T1 (ko)
WO (1) WO2003011277A2 (ko)
ZA (1) ZA200400658B (ko)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169750B2 (en) * 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
MXPA04000982A (es) 2001-07-31 2004-04-20 Anormed Inc Metodos para movilizar celulas progenitoras/madre.
US7354932B2 (en) * 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
MXPA04006136A (es) 2001-12-21 2004-11-01 Anormed Inc Compuestos heterociclicos que se unen a receptor de quimiocina con eficacia incrementada.
KR101160698B1 (ko) * 2003-06-27 2012-06-28 아사히 가세이 가부시키가이샤 세포 분화 억제제, 이것을 이용하는 세포 배양 방법, 배양 배지 및 배양된 세포주
WO2005002522A2 (en) * 2003-06-30 2005-01-13 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for treating tissue ischemia
EP1656156A2 (en) 2003-08-13 2006-05-17 Children's Hospital Medical Center Mobilization of hematopoietic cells
US20050069553A1 (en) 2003-08-13 2005-03-31 Yi Zheng Chimeric peptides for the regulation of GTPases
IL158868A0 (en) * 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
WO2005103721A1 (en) * 2004-04-20 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 4 (cxcr4)
JP2008509928A (ja) * 2004-08-13 2008-04-03 アノーメド インコーポレイテッド 前駆／幹細胞を動員するためのケモカインの組み合わせ
US8182806B2 (en) * 2004-09-07 2012-05-22 Johnson Lanny L Synovial villi for use with tissue engineering
US7785582B2 (en) * 2004-09-07 2010-08-31 Johnson Lanny L Use of synovium and omentum for tissue engineering
CA2586765A1 (en) 2004-11-05 2006-12-28 The General Hospital Corporation Purposeful movement of human migratory cells away from an agent source
EP1904084B1 (en) 2005-06-13 2013-04-24 Cleveland Biolabs, Inc. Methods of protecting against apoptosis using lipopeptides
BRPI0615180A2 (pt) * 2005-08-19 2011-05-03 Genzyme Corp método para intensificar a quimioterapia
EP1924606A4 (en) * 2005-08-25 2010-01-13 Repair Technologies Inc DEVICES, COMPOSITIONS AND METHODS FOR PROTECTING AND REPAIRING CELLS AND TISSUE
US8518349B2 (en) 2005-09-12 2013-08-27 Lanny Johnson Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US7927630B2 (en) * 2005-09-12 2011-04-19 Johnson Lanny L Use of autologous sediment from fluid aspirates as vehicles for drug delivery
US20070116680A1 (en) * 2005-11-18 2007-05-24 Rensselaer Polytechnic Institute Stem cells within gel microenvironments
MX2008010895A (es) * 2006-02-24 2008-09-03 Genzyme Corp Metodos para aumentar el flujo sanguineo y/o promover la regeneracion de tejidos.
WO2007108689A2 (en) * 2006-03-21 2007-09-27 Stichting Skeletal Tissue Engineering Method for induction of differentiation of stem and progenitor cells
JP2010507567A (ja) * 2006-08-07 2010-03-11 ジェンザイム・コーポレーション 併用療法
US7883698B2 (en) * 2007-01-17 2011-02-08 Maria Michejda Isolation and preservation of fetal hematopoietic and mesencymal system cells from non-controversial materials and/or tissues resulting from miscarriages and methods of therapeutic use
US20110245265A1 (en) * 2008-08-29 2011-10-06 Genzyme Corporation Cxcr4 antagonists for kidney injury
EP2493295A4 (en) 2009-10-28 2013-05-08 Ford Henry Health System METHOD FOR MINIMIZING LESIONS DUE TO RADIATION EXPOSURE
CN101716167B (zh) * 2009-12-08 2011-12-28 中国人民解放军军事医学科学院野战输血研究所 一类饱和胺类化合物在制备外周血造血干细胞动员药物中的应用
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
MX365242B (es) 2011-05-16 2019-05-28 Genzyme Corp El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim.
WO2014152629A1 (en) * 2013-03-15 2014-09-25 Miller Leonard B Combination therapy to improve soft tissue healing, fat graft healing, endochondral bone healing and osteointegration
US9988973B2 (en) 2015-01-06 2018-06-05 Hamilton Sundstrand Corporation Water injector for aviation cooling system
WO2017049208A1 (en) 2015-09-18 2017-03-23 The General Hospital Corporation Dba Massachusetts General Hospital Localized delivery of anti-fugetactic agent for treatment of cancer
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
EP3389634B1 (en) 2015-12-14 2021-10-06 X4 Pharmaceuticals, Inc. Methods for treating cancer
US11433136B2 (en) 2015-12-18 2022-09-06 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
SI3393468T1 (sl) 2015-12-22 2023-01-31 X4 Pharmaceuticals, Inc. Postopki za zdravljenje bolezni imunske pomanjkljivosti
JP2019510785A (ja) 2016-04-08 2019-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置する方法
WO2017216373A1 (en) * 2016-06-16 2017-12-21 Centre National De La Recherche Scientifique Cxcr4 receptor-binding compounds useful for increasing interferon level
US10759796B2 (en) 2016-06-21 2020-09-01 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
EP3471726A4 (en) 2016-06-21 2019-10-09 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
EP3509609A4 (en) 2016-09-09 2021-01-20 The General Hospital Corporation HYBRID HSP PROTEIN WITH ANTI-CHEMIO-REPELLENT AGENT FOR CANCER TREATMENT
US11453706B2 (en) 2016-09-09 2022-09-27 The General Hospital Corporation HSP fusion protein with anti-chemorepellant agent for treatment of infectious disease
US11364264B2 (en) 2016-09-09 2022-06-21 The General Hospital Corporation Ex vivo antigen-presenting cells or activated CD-positive T cells for treatment of cancer
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
WO2019113375A2 (en) * 2017-12-06 2019-06-13 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US10058573B1 (en) 2017-12-06 2018-08-28 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem cells
KR20200103018A (ko) * 2017-12-19 2020-09-01 주식회사 지피씨알 Gpcr 헤테로머 억제제 및 이의 용도
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
US20230104658A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica Nv Methods of increasing progenitor cell production

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US562476A (en) * 1896-06-23 Combined fence-wire reel and straightener
US4111199A (en) * 1977-03-31 1978-09-05 Isaac Djerassi Method of collecting transfusable granulocytes by gravity leukopheresis
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
DE3728525A1 (de) 1987-08-24 1989-03-16 Schering Ag Mehrkernige substituierte komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
FR2644453A1 (fr) 1989-03-20 1990-09-21 Centre Nat Rech Scient Procede de preparation de tetramines cycliques monofonctionnalisees
WO1991005762A1 (en) 1989-10-23 1991-05-02 Cockbain, Julian, Roderick, Michaelson Multi-site metal chelating agents
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
FR2672051B1 (fr) 1991-01-24 1993-05-21 Guerbet Sa Nouveaux ligands macrocycliques azotes, procede de preparation, complexes polymetalliques, composition de diagnostic et therapeutique.
GB9105489D0 (en) 1991-03-15 1991-05-01 Johnson Matthey Plc Improvements in chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
AU689454B2 (en) 1992-11-13 1998-04-02 Board Of Regents Of The University Of Washington, The Peripheralization of hematopoietic stem cells
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
JPH08127539A (ja) * 1994-10-31 1996-05-21 Ajinomoto Co Inc ヒトｉｌ−１１を含有する末梢血幹細胞増加剤
US5612478A (en) 1995-03-30 1997-03-18 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
US5606053A (en) 1995-05-02 1997-02-25 Johnson Matthey Plc Process for preparing 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11-tetraazacyclotetradecane
JPH0952824A (ja) * 1995-06-05 1997-02-25 Nippon Kayaku Co Ltd 末梢血液中の造血幹細胞数を増加するための薬剤
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US5811544A (en) * 1995-08-28 1998-09-22 Johnson Matthey Plc Process for preparing 1,4,8,11-tetraazacyclotetradecane
WO2000018885A1 (en) * 1998-09-29 2000-04-06 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
NZ528767A (en) * 1998-03-30 2005-08-26 Northwest Biotherapeutics Inc Therapeutic and diagnostic applications based on the role of the CXCR-4 gene in tumorigenesis
AU4696899A (en) * 1998-06-19 2000-01-05 General Hospital Corporation, The Modulating platelet function
CA2244554A1 (en) * 1998-07-30 2000-01-30 Vasogen Inc. Inhibition of graft versus host disease
JP2002529502A (ja) * 1998-11-17 2002-09-10 スミスクライン・ビーチャム・コーポレイション 血小板減少症の治療法
EP1016413A1 (en) * 1998-12-30 2000-07-05 Applied Research Systems ARS Holding N.V. Human growth hormone to stimulate mobilization of pluripotent hematopoietic stem cells
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
EP1163238B1 (en) 1999-03-24 2006-05-31 Anormed Inc. Chemokine recpetor binding heterocyclic compounds
EP1189609A4 (en) * 1999-05-03 2002-10-30 Smithkline Beecham Corp CXCR-4 RECEPTOR ANTAGONISTS AND THROMBOPOIETIN MIMETIKA
CN100335478C (zh) 1999-12-17 2007-09-05 阿诺麦德股份有限公司 结合趋化因子受体的杂环化合物
JP2003532683A (ja) 2000-05-09 2003-11-05 ザ ユニバーシティ オブ ブリティッシュ コロンビア 造血細胞のｃｘｃｒ４アンタゴニスト治療
US20040131585A1 (en) * 2000-06-05 2004-07-08 Silviu Itescu Identification and use og human bone marrow-derived endothelial progenitor cells to improve myocardial function after ischemic injury
WO2002022599A2 (en) 2000-09-15 2002-03-21 Anormed Inc. Chemokine receptor binding heterocyclic compounds
US6734191B2 (en) 2000-09-15 2004-05-11 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
AU9156901A (en) 2000-09-15 2002-03-26 Anormed Inc Chemokine receptor binding heterocyclic compounds
MXPA03002772A (es) 2000-09-29 2003-07-28 Anormed Inc Procedimiento para la preparacion de poliaminas ciclicas que contienen nitrogeno en el anillo n-1 protegidos y productos de los mismos.
US6750339B2 (en) 2001-01-23 2004-06-15 The Procter And Gamble Company Primary intermediates for oxidative coloration of hair
US7169750B2 (en) 2001-07-31 2007-01-30 Anormed, Inc. Methods to mobilize progenitor/stem cells
MXPA04000982A (es) 2001-07-31 2004-04-20 Anormed Inc Metodos para movilizar celulas progenitoras/madre.
MXPA04006136A (es) 2001-12-21 2004-11-01 Anormed Inc Compuestos heterociclicos que se unen a receptor de quimiocina con eficacia incrementada.
DE102014206089B4 (de) 2014-03-31 2018-01-18 BSH Hausgeräte GmbH Haushaltskältegerät mit einer Spendereinheit mit zwei Verschlusselementen an einem Ausführkanal

Also Published As

Publication number Publication date
LUC00139I1 (ko) 2019-11-27
CY2012017I2 (el) 2015-08-05
US20060223180A1 (en) 2006-10-05
NL301031I2 (nl) 2020-07-20
FR19C1058I1 (ko) 2019-11-22
US20030130250A1 (en) 2003-07-10
KR100996378B1 (ko) 2010-11-25
US7897590B2 (en) 2011-03-01
JP2004538303A (ja) 2004-12-24
PT1411918E (pt) 2012-03-06
SI2371361T1 (sl) 2019-10-30
US20190216773A1 (en) 2019-07-18
LU92033I2 (fr) 2012-08-27
NO20150674A1 (no) 2015-05-27
CN102302493B (zh) 2015-08-12
NO20040407L (no) 2004-03-19
LT2371361T (lt) 2019-09-10
ATE538785T1 (de) 2012-01-15
BRPI0211570B8 (pt) 2021-05-25
CN1561208A (zh) 2005-01-05
DK1411918T3 (da) 2012-04-23
CA2455559C (en) 2012-01-10
CY2012017I1 (el) 2015-08-05
US20080063624A1 (en) 2008-03-13
NO344632B1 (no) 2020-02-17
ES2380009T3 (es) 2012-05-07
US20130273009A1 (en) 2013-10-17
US20170049747A1 (en) 2017-02-23
CN102302493A (zh) 2012-01-04
LU92033I9 (ko) 2019-01-03
LTPA2019018I1 (lt) 2019-12-10
RU2309741C2 (ru) 2007-11-10
SI1411918T1 (sl) 2012-04-30
KR20040020075A (ko) 2004-03-06
HUP0402360A2 (hu) 2005-02-28
EP3632425A1 (en) 2020-04-08
FR12C0042I1 (fr) 2012-08-10
IL159312A (en) 2015-05-31
US7935692B2 (en) 2011-05-03
NL300537I2 (ko) 2017-02-02
WO2003011277A2 (en) 2003-02-13
CY2019038I1 (el) 2020-05-29
PT2371361T (pt) 2019-09-10
EP1411918A4 (en) 2007-11-14
RU2004105961A (ru) 2005-03-20
US20060193826A1 (en) 2006-08-31
BE2019C544I2 (ko) 2021-07-19
EP1411918B1 (en) 2011-12-28
NO336989B1 (no) 2015-12-14
LTC2371361I2 (lt) 2021-09-27
US20150246019A1 (en) 2015-09-03
IL159312A0 (en) 2004-06-01
KR20090130152A (ko) 2009-12-17
NL301031I1 (nl) 2020-02-05
BRPI0211570B1 (pt) 2020-01-28
MXPA04000982A (es) 2004-04-20
PL364673A1 (en) 2004-12-13
CN1561208B (zh) 2010-11-10
EP2371361A1 (en) 2011-10-05
NZ530169A (en) 2007-04-27
EP1411918A2 (en) 2004-04-28
JP2008195730A (ja) 2008-08-28
WO2003011277A3 (en) 2003-05-22
CY1122199T1 (el) 2020-05-29
CY2019038I2 (el) 2020-05-29
US20110129448A1 (en) 2011-06-02
CA2455559A1 (en) 2003-02-13
ES2742730T3 (es) 2020-02-17
BR0211570A (pt) 2004-07-13
LUC00139I2 (ko) 2021-02-10
US6987102B2 (en) 2006-01-17
EP2371361B1 (en) 2019-08-07
AU2002318927B2 (en) 2007-01-04
NO2020003I1 (no) 2020-03-05
CY1112633T1 (el) 2015-08-05
NO2016011I1 (no) 2016-06-10
JP5137288B2 (ja) 2013-02-06
ZA200400658B (en) 2005-07-27
DK2371361T3 (da) 2019-08-19
FR19C1058I2 (fr) 2020-10-23

Similar Documents

Publication Publication Date Title
LUC00139I2 (ko)
AP1497A (en) Methods and compositions to enhance white blood cell count.
HUP0004259A2 (hu) VLA-4 által mediált leukocita adhéziót gátló szubsztituált fenilalanin-származékok, ezeket tartalmazó gyógyászati készítmények
KR930006027A (ko) 엔케팔리나제 및 안지오텐신 전환 효소(ace)의 억제제로서 유용한 2-치환 인단-2-메르캅토아세틸아미드 유도체
KR920012082A (ko) Ace 억제제로서 유용한 신규 아미노 및 니트로 함유 삼환식 화합물
ES2164164T3 (es) Derivados de aminotetrazol utiles como inhibidores de oxido nitrico sintasa.
WO1994019343A3 (en) Novel use as anti-inflammatory agents for bis-heterocyclic compounds and pharmaceutical compositions thereof
EA200001078A1 (ru) НОВЫЕ СОЕДИНЕНИЯ 12,13-(ПИРАНОЗИЛ)-ИНДОЛО[2,3-α]ПИРРОЛО[3,4-С]КАРБАЗОЛА И 12,13-(ПИРАНОЗИЛ)-ФУРО[3,4-C]ИНДОЛО[2,3-α]КАРБАЗОЛА, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ИХ
NO852514L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 8-alkyltio-2-piperazino-pyrimido (5,4-d) pyrimidin-derivater.
WO1999023092A3 (en) 3-aminoalkylamino-2h-1,4-benzoxa(thia-)zines and pharmaceutical compositions containing them
AR026222A1 (es) Compuestos derivados de acido antranilico
OA09239A (fr) "Nouveaux céphèmes et procédés pour leur préparation".
WO2007106063A3 (en) Methods for increasing blood flow and/or promoting tissue regeneration
ES8605524A1 (es) Procedimiento para preparar tieno- y furo-(2,3-c)-pirroles
EA200000527A2 (ru) Новые бициклические амино-пиразиноновые соединения, способ их получения и фармацевтические композиции, содержащие их
ATE398131T1 (de) Kondensierte camptothecine als antitumormittel

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: ADDITION OF INVENTOR: DALE C. DAVID - BROXMEYER, HAL E

REV Revocation after opposition